Evidence map›Paper›PMID 41123891›Full record

ArticleJAMA network open2025

Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments.

Tess Stopczynski, Olla Hamdan, Justin Z Amarin, James W Antoon, Laura S Stewart, Haya Hayek, James Chappell, Andrew J Spieker, Eileen J Klein, Janet A Englund and 14 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Tess StopczynskiDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Olla HamdanDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Justin Z AmarinDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
James W AntoonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Laura S StewartDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Haya HayekDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
James ChappellDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Andrew J SpiekerDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Eileen J KleinSeattle Children's Research Institute, Seattle, Washington.
Janet A EnglundSeattle Children's Research Institute, Seattle, Washington.
Geoffrey A WeinbergUniversity of Rochester School of Medicine and Dentistry & UR-Golisano Children's Hospital, Rochester, New York.
Peter G SzilagyiUniversity of Rochester School of Medicine and Dentistry & UR-Golisano Children's Hospital, Rochester, New York.
John V WilliamsUPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Marian G MichaelsUPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Julie A BoomTexas Children's Hospital and Baylor College of Medicine, Houston.
Leila C SahniTexas Children's Hospital and Baylor College of Medicine, Houston.
Mary Allen StaatCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Elizabeth P SchlaudeckerCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Jennifer E SchusterDepartment of Pediatrics, University of Missouri-Kansas City, Children's Mercy Hospital, Kansas City.
Rangaraj SelvaranganDepartment of Pathology & Laboratory Medicine, University of Missouri Kansas City, Children's Mercy Hospital, Kansas City.
Ayzsa TannisCenters for Disease Control and Prevention, Atlanta, Georgia.
Heidi L MolineCenters for Disease Control and Prevention, Atlanta, Georgia.
Samantha M OlsonCenters for Disease Control and Prevention, Atlanta, Georgia.
Natasha B HalasaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

NCIRD CDC HHS U01 IP001049NCIRD CDC HHS U01 IP001158
6 · The paper itself

Abstract

Importance: Despite national recommendations, antiviral prescribing in emergency departments (EDs) for children at higher risk of severe influenza, such as those younger than 5 years and those with specific underlying conditions, remains low. Objective: To assess whether there were changes in antiviral prescribing for children at higher risk of severe influenza in academic pediatric EDs before the COVID-19 pandemic (2016-2020) vs the late pandemic period (2021-2023). Design, Setting, and Participants: This multicenter, cross-sectional study included influenza-positive children younger than 18 years presenting to the ED at 1 of 7 US pediatric academic hospitals participating in the Centers for Disease Control and Prevention's New Vaccine Surveillance Network. The analysis focused on children at higher risk of severe influenza seen in the ED from December 1, 2016, to June 30, 2023. Exposure: High risk of severe influenza. Main Outcomes and Measures: The primary outcome was antiviral prescribing. Children with influenza who met the criteria for higher risk of severe influenza were included. Antiviral prescribing practices were compared across the prepandemic and late pandemic periods. Mixed-effects logistic regression was used to identify factors associated with prescribing during the late pandemic period. Results: Of 3378 influenza-positive children (median [IQR] age, 3.9 [1.8-7.2] years), 2514 (74.4%; 1363 male [40.3%]) were classified as having higher risk of severe influenza during the prepandemic and late pandemic periods. Antiviral prescriptions decreased from 32.2% (622 of 1931 children) before the pandemic to 15.6% (91 of 583 children) in the late pandemic period, representing a 53% relative decrease. In the late pandemic period, symptom duration less than 2 days (adjusted odds ratio, 4.08; 95% CI, 2.49-6.71) and clinical influenza testing (adjusted odds ratio, 17.20; 95% CI, 4.08-72.37) were significantly associated with antiviral prescribing. Conclusions and Relevance: This multicenter, cross-sectional study of children with influenza in EDs found that, for children at higher risk of severe influenza illness, influenza antiviral prescribing decreased during the COVID-19 pandemic compared with prepandemic levels, despite unchanged treatment guidelines. Interventions are needed to support guideline-concordant prescribing in this population.

Indexed as

Antiviral AgentsDrug PrescriptionsEmergency Service, HospitalInfluenza, HumanPractice Patterns, Physicians'AdolescentChildChild, PreschoolCOVID-19Cross-Sectional StudiesFemaleHumansInfantMalePandemicsSARS-CoV-2Antiviral Agents

Identifiers

PMID41123891
PMCPMC12547580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.